INAB IN8bio Inc

$INAB be careful when a company starts pumping its ticker on X ticker slowly rising on low volume...can be a trap

$INAB lol...Sharing verified updates directly from IN8bio's official LinkedIn and IR releases isn't a "paid gig"—it's called sharing factual data. Offering help was just simple courtesy toward someone who couldn't spend 10 seconds checking a primary source before labeling an honest, verified post as "illegitimate." Resorting to lazy "paid pumper" tropes when faced with real filings proves you add zero value to this board. Enjoy the block. $INAB

$INAB LOL. I’ve been following this company for over 3 years and know the management team and board members well. They are serious, highly competent professionals focused on science and execution, not hype. Regarding volume: if you actually check the data, current volume is running slightly ABOVE the daily average. This is a nano-cap biotech, so lower absolute liquidity is completely standard for this market cap until a major catalyst hits. Sharing official company updates and pipeline insights on X or LinkedIn isn't a "trap", it's just basic due diligence.

$INAB In MimiVax's failed trial with newly diagnosed GBM they state: "MimiVax's cancer vaccine missed the primary endpoint of a phase 2 study in patients with newly diagnosed glioblastoma. The New York-based company evaluated the peptide-mimic immunotherapeutic vaccine, called SurVaxM, against placebo in 233 evaluable patients with newly diagnosed brain cancer. SurVaxM was tied to a median overall survival (OS) of 22.8 months compared to 20.3 months for the placebo cohort." IN8bio trial with with newly diagnosed GBM they state: "Overall survival (OS) was equally notable: median OS in repeat-dose patients was 19.5 months, compared to a historical SOC mOS of approximately 14.6 months in this patient population." As an investor in In8bio my concern is the MimiVax latest trial not historical data shows mOS as 20.3 months for placebo. The In8bio showed mOS for their repeat-dose patients of 19.5 months. Looking at these current data it makes In8bio really showing no affect at all to mOS.

Before questioning legitimacy on a public board, maybe try doing 30 seconds of basic due diligence. The source is IN8bio’s official LinkedIn page and IR press releases—which is where actual biotech companies publish their corporate decks, not on X. Still having doubts or struggling to find it? Let me know and I'll gladly drop the direct link to walk you through it. $INAB